Corvus reports Q4 net loss of $9.8M; identifies predictive biomarker for CPI-818 in T-cell lymphoma

Corvus Pharmaceuticals, Inc.

Cash $42.3M at Dec 31, 2022 (from $69.5M); 2023 operating burn guided $19-22M with year-end cash $20-23M.
Q4 2022 net loss $9.8M vs $9.2M year ago; R&D expense $4.1M.
CPI-818 Phase 1/1b: ALC >900 biomarker identified; 4/8 biomarker-positive patients had objective responses.
Median PFS 28.1 months in ALC>900 patients vs 2.1 months in ALC<900 patients (n=13 evaluable).
Atopic dermatitis trial delayed to conserve cash; FDA meeting for Phase 3 lymphoma trial planned for 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Corvus Pharmaceuticals, Inc. reported financial results for the fourth quarter and year ended December 31, 2022.

Period: the fourth quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 28, 2023, Corvus Pharmaceuticals, Inc. issued a press release regarding, among other matters, its financial results for the fourth quarter and full year ended December 31, 2022 and its financial position as of December 31, 2022, and provided a business update.

View on SEC.gov

Browse all earnings releases →

Corvus Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-23-001948

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.